Chronic Wounds - Market Insight, Epidemiology And Market Forecast - 2032

DelveInsight's 'Chronic Wounds - Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Chronic Wounds, historical and forecasted epidemiology as well as the Chronic Wounds market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Chronic Wounds market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Chronic Wounds market size from 2019 to 2032. The Report also covers current Chronic Wounds treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032.

Chronic Wounds- Disease Understanding and Treatment Algorithm

Chronic wounds, are defined as the wounds with an inability to heal within an anticipated time frame. They are widespread and frequently mistreated. A wound is considered chronic or non-healing when it has not fully healed even after four to six weeks of screening. Venous ulcer (VU [Vein ulcers, arterial ulcers]), diabetic foot ulcers (DFU), and pressure ulcers (PU) are examples of common chronic wound types.

While different etiologies of chronic wounds are associated with slightly different symptoms, the most common way to recognize a chronic wound is by its elevated, hyperproliferative, yet immobile wound edge. There will be inflammation in the vicinity of the wound, which could harm the healing process. Other common signs and symptom checklist include: Bleeding, swelling, pain or blistering, darkened skin around the wound, difficulty moving the injured area, enlarged or deepened injury, fever, itching, milky pus, and warmth or heat when touched.

Chronic Wounds Diagnosis

The first step in the clinical evaluation of a wound is to decide if it is an acute or chronic wound. Wound assessment starts with a careful physical examination. Location, size and depth of wound; presence of drainage; and tissue type are documented. Based on location and appearance, most chronic wounds can be classified by etiology, allowing for appropriate assessment and treatment recommendations.

Continued in the report…..

Chronic Wounds Treatment

A thorough assessment of the patient and the wound will guide subsequent treatment by elucidating underlying areas of concern that need to be addressed. Diabetic patients frequently need improved control of their hyperglycemia, renal insufficiency, nutrition, and other associated medical comorbidities that may adversely affect the healing of their wound(s). Patients with VLUs might often have hemodynamic perturbations requiring improved medical management. PU patients, often bedridden from inter-current illness, will have significant nutritional deficits that need to be corrected to optimize tissue repair.

Treatment primarily focuses on treating the cause. First, all chronic wounds should be managed according to the principle of TIME: tissue debridement (in all cases except arterial ulcers), infection control, fluid balance, and wound margins. Effective management of infection in chronic wounds includes removal of necrotic tissue, cellular debris, and biofilm by debridement, and appropriate use of antimicrobial agents (including topical antiseptics and systemic antibiotics).

Continued in the report…..

Chronic Wounds Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Chronic Wounds, and Type-specific Diagnosed Prevalent Cases of Chronic Wounds, in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Key Findings

• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Chronic Wounds in the 7MM were 7,037,816 in 2021.
• The highest total diagnosed prevalent cases of Chronic Wounds were accounted by the US in 2021 (4,140,580 cases), which are expected to show a rise in the future.
• Among the European countries, Germany had the highest diagnosed prevalent cases of Chronic Wounds with 602,682 cases, followed by France, which had 486,121 cases in 2021. On the other hand, in the same year Spain had the lowest diagnosed prevalent population (336,316 cases).
• Japan had 553,799 total diagnosed prevalent cases of Chronic Wounds in 2021, accounting for approximately 8% in the 7MM.
• During the peak year of COVID-19 pandemic, a steep decline in the cases of Chronic Wounds was recorded throughout the 7MM. These cases are anticipated to rise again during the forecasted period (2022-2032).

Chronic Wounds Epidemiology

The epidemiology segment also provides the Chronic Wounds epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Chronic Wounds Drug Chapters

The drug chapter segment of the Chronic Wounds report encloses the detailed analysis of Chronic Wounds drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Chronic Wounds clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.

Chronic Wounds Marketed Drugs

Regranex (becaplermin): Smith & Nephew

REGRANEX is indicated for treating lower extremity diabetic neuropathic ulcers that extend into the SC tissue or beyond and have an adequate blood supply when used as an adjunct to, and not a substitute for, good ulcer care practices, including initial sharp debridement, pressure relief, and infection control.

Products detail in the report…

List to be continued in the report…

Chronic Wounds Emerging Drugs

ON101: Oneness Biotech

ON101 is a new botanical drug ointment that possesses the function of diabetic wound healing and high safety. The main mechanisms of ON101 are to reduce wound inflammation, increase epithelialization of the epidermal tissues, promote collagen production, and decrease granulation tissue development in the wound. The active pharmaceutical ingredient (API) of ON101 is composed of extracts from two commonly used traditional Chinese herbal medicine, Plectranthus amboinicus, and the Centella asiatica.

TTAX01: Biotissue

TTAX01 is being developed by Biotissue to manage DFU and nonhealing wounds. It is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determining donor eligibility and placenta suitability. The company's proprietary technology CRYOTEK process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue, is being used. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP).

Products detail in the report…

List to be continued in the report…

Chronic Wounds Market Outlook

Numerous elements must cooperate for a superficial wound to heal, moreover, wound dressings and treatments have advanced significantly to address potential obstacles to wound healing, from infection to hypoxia. Even under ideal conditions, the strength of the injured tissue never restores, and several aberrant healing states can lead to persistent nonhealing wounds. Despite significant advances in technological innovation and the advent of various wound treatments, nonhealing wounds continue to challenge physicians. Various nonsurgical approaches have been developed, and many drugs have been introduced to assist in managing such wounds.

Debridement is the removal of nonviable wound tissue, and it can be performed using surgical, autolytic, enzymatic, biologic, or mechanical methods. Although several moisture-retentive dressings are available to manage chronic wounds, the best dressing is the one that keeps the wound moist but not too wet or dry. While there are multiple types of moisture-retentive dressings, the five basic categories include films, foams, hydrocolloids, alginates, and hydrogels.

In addition to dressings, NPWT (also known as vacuum-assisted closure) has been used primarily in chronic wound management for diabetic foot ulcers and pressure ulcers. With the advancement of chronic wounds, there is a need for a more advanced technique to cure this situation.

Continued in the report…..

Key Findings

• The therapeutic market size of Chronic Wounds in the 7MM was USD 5,232 million in 2021.
• The United States accounts for the highest market size of Chronic Wounds approximately 73% of the total market size in the 7MM in 2021, in comparison to the other major markets i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain),and Japan.
• Among the EU5 countries, Germany had the highest market size with USD 292 million in 2021, while Spain had the lowest market size of Chronic Wounds with USD 165 million in 2021.
• The market size for Chronic Wounds in Japan was estimated to be USD 300 Million in 2021, which accounts for 6% of the total 7MM market.
• With the expected launch of upcoming therapies, such as TTAX01, ON101 Cream, and others the total market size of Chronic Wounds is expected to show change in the upcoming years.

The United States Market Outlook

This section provides the total Chronic Wounds market size and market size by therapies in the United States.

EU-5 Market Outlook

The total Chronic Wounds market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Chronic Wounds market size and market size by therapies in Japan are provided.

Chronic Wounds Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Wounds or expected to get launched in the market during the study period 2019-2032. The analysis covers Chronic Wounds market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Wounds Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Chronic Wounds emerging therapies.

Reimbursement Scenario in Chronic Wounds

Chronic wounds affect 2% of the adult population in developed countries, and a few effective treatments exist. The economic burden is increasing due to the high cost, leading to the escape of the patient from proper treatment. Reimbursement is a crucial factor affecting the drug's market access. Often, the decision to reimburse comes down to the drug's price relative to the benefit it produces in treated patients. The chances of prices of chronic wound medications are likely to be at the higher end, which might make access and reimbursement somewhat difficult in the future. However, there could be a slight possibility that reimbursement authorities are willing to pay a premium for innovative medicines; for that, efficacy and safety profile must be top-notch.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Chronic Wounds market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Reports

• The report covers the descriptive overview of Chronic Wounds, explaining its signs and symptoms, causes, classification, and currently available therapies.
• Comprehensive insight has been provided into the Chronic Wounds epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Wounds is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Chronic Wounds market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Chronic Wounds market.

Report Highlights:

• The robust pipeline with novel MOA and oral ROA and increasing prevalence will positively drive the Chronic Wounds market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Wounds R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition and underlying cause.
• Major players are involved in developing therapies for Chronic Wounds. The launch of emerging therapies will significantly impact the Chronic Wounds market.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Chronic Wounds Report Insights

• Patient Population
• Therapeutic Approaches
• Chronic Wounds Pipeline Analysis
• Chronic Wounds Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Chronic Wounds Report Key Strengths

• 11-Years Forecast
• 7MM Coverage
• Chronic Wounds Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Chronic Wounds Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• SWOT analysis

Key Questions

Market Insights:

• What was the Chronic Wounds market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Chronic Wounds total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Chronic Wounds market size during the forecast period (2022-2032)?
• At what CAGR, the Chronic Wounds market is expected to grow at the 7MM level during the forecast period (2022-2032)?
• What would be the Chronic Wounds market outlook across the 7MM during the forecast period (2022-2032)?
• What would be the Chronic Wounds market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden, and unmet needs of Chronic Wounds?
• What is the historical Chronic Wounds patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient population of Chronic Wounds at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Chronic Wounds?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Chronic Wounds during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Chronic Wounds along with the approved therapy?
• What are the current treatment guidelines for the treatment of Chronic Wounds in the US, Europe, And Japan?
• What are the Chronic Wounds marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Chronic Wounds?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Chronic Wounds?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Wounds therapies?
• What are the recent therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Wounds and their status?
• What are the key designations that have been granted for the emerging therapies for Chronic Wounds?
• What are the 7MM historical and forecasted market of Chronic Wounds?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Chronic Wounds.
• To understand the future market competition in the Chronic Wounds market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Chronic Wounds in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Chronic Wounds market.
• To understand the future market competition in the Chronic Wounds market.